Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aurinia Pharmaceuticals Inc - Common Shares
(NQ:
AUPH
)
8.180
+0.070 (+0.86%)
Streaming Delayed Price
Updated: 9:32 AM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
27,093
Open
8.170
Bid (Size)
8.180 (4)
Ask (Size)
8.210 (8)
Prev. Close
8.110
Today's Range
8.130 - 8.190
52wk Range
4.710 - 10.67
Shares Outstanding
128,395,927
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet
March 07, 2025
Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.
Via
Stocktwits
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations
February 27, 2025
Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.
Via
Benzinga
Performance
YTD
-6.73%
-6.73%
1 Month
+7.49%
+7.49%
3 Month
-15.58%
-15.58%
6 Month
+24.32%
+24.32%
1 Year
+55.81%
+55.81%
More News
Read More
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
February 27, 2025
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Earnings Scheduled For February 27, 2025
February 27, 2025
Via
Benzinga
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
February 20, 2025
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
November 18, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
November 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia to Participate in Jefferies London Healthcare Conference
November 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
November 07, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
November 07, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
October 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
September 24, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
September 13, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Board Restructuring
September 12, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
September 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
August 01, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
July 19, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia to Participate in Upcoming Investor Healthcare Conferences
July 02, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces 2024 Annual General Meeting Results
June 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
June 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
June 04, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Provides Update on Proxy Statement
June 03, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
May 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.